Guardant Health, Inc. GH
We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. 10-K, Item 1
- Employees
- 2,506
- Headquarters
- Palo Alto, CA
- Next results
- around Jan 11, 2027
GH among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
11 new risk paragraphs. 10-K filed Feb 19, 2026 against Feb 20, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
10 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 10 checks found nothing to note
-
Receivables +25.0% ($110.3M to $137.8M) vs revenue +32.9% ($739.0M to $982.0M), -7.9 pts apart
-
Cash from operations −$184.8M vs net income −$416.3M (FY ending Dec 31, 2025)
-
Inventory +20.8% ($71.1M to $85.9M) vs revenue +32.9% ($739.0M to $982.0M), -12.1 pts apart
7 more checks with nothing to note
-
Same auditor in both 10-Ks: Deloitte & Touche LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
11 paragraphs in Risk Factors that were not in the 10-K filed Feb 20, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
Changes to FDA Regulation of Companion Diagnostics Could Adversely Affect Our Business and Competitive Position The FDA has proposed reclassifying certain companion diagnostic tests from Class III devices requiring PMA to Class II devices subject to special controls and the 510(k) process. Although the proposal is not final and its…
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
Our increasing usage of artificial intelligence technologies may expose us to operational, regulatory, legal, and reputational risks. We currently utilize, and expect to increasingly rely on, artificial intelligence (AI) in our operations and certain of our products, and we may continue to adopt and integrate AI, including generative AI…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $449.5M | $563.9M | $739.0M | $982.0M |
| Net income | −$654.6M | −$479.4M | −$436.4M | −$416.3M |
| Operating cash flow | −$309.5M | −$325.0M | −$239.9M | −$184.8M |
| Free cash flow | −$386.9M | −$345.5M | −$274.9M | −$233.1M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$982.0M ▲ 32.9% in FY2025−$416.3M in FY2025−$233.1M in FY2025
Recent filings
5 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 5, 2026Terilyn Monroe (Chief People Officer) adopted a 10b5-1 trading plan reported in the 10-Q, runs to Oct 6, 2027
-
8-KNov 5, 2026Quarterly results 8-K item 2.02
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
OfficerNov 3, 2026CAO change Parks and any other person pursuant to which he was appointed as Chief Accounting Officer of the Company, and he is not a party to, nor does he have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K.
-
8-KNov 3, 2026Director or officer change 8-K item 5.02
About the company
Guardant Health, Inc., Palo Alto, CA · from the 10-K filed Feb 19, 2026
We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics. Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.
- Headquarters
- Palo Alto, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 5, 2026
- Incorporated in
- DE
Employees, at the top of the page: "As of December 31, 2025, we had 2,506 employees, 2,490 of which are full-time employees and approximately 2,278 of which are in the U" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 19, 2026 (open at SEC), compared with the 10-K filed Feb 20, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GH/export.csv") into a cell.